Acadia Pharmaceuticals will pay Saniona $28 million upfront and up to $582 million in milestone payments for SAN711, an ...

Idor­sia is mak­ing moves to stretch its cash re­serves fur­ther. The Swiss drug­mak­er said it is nar­row­ing its ...

President-elect Trump selected Jay Bhattacharya, Stanford professor and Covid-19 lockdown critic, to lead NIH, and Jim ...

The Biden ad­min­is­tra­tion pro­posed a new rule Tues­day that would ex­pand Medicare and Med­ic­aid cov­er­age of pop­u­lar ...

Axsome Therapeutics’ narcolepsy drug AXS-12 hit the primary endpoint in its Phase 3 ENCORE trial, showing a statistically ...

Sarepta Therapeutics and Arrowhead Pharmaceuticals teamed up on an siRNA partnership that has one of the biggest promises of ...

Alladapt Immunotherapeutics, a well-financed biotech working in the food allergy field, shut down following talks with the ...

FDA extends review of Soleno Therapeutics' diazoxide choline extended-release tablets for Prader-Willi syndrome by three ...

Agilent Technologies announced reorganization into three business units: life sciences and diagnostics led by Simon May, ...

Aviceda seeks $200M for AVD-104 trial, Nerviano reacquires NMS-293 from Merck KGaA, MaaT Pharma reports positive Phase 1b ALS drug data, Secretome raises $20.4M, 35Pharma secures $35M Series C, ...

Roche is acquiring its cell therapy and genomic medicines partner Poseida Therapeutics, the companies said Tuesday morning.

Roche's tiragolumab failed to meet overall survival endpoint in Phase 3 SKYSCRAPER-01 trial when combined with Tecentriq for ...